Cite
HARVARD Citation
D'Arena, G. et al. (2017). Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leukemia & lymphoma. 58 (11), pp. 2633-2641. [Online].